^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AUR-106

    i
    Other names: AUR-106, AUR106, AUR 106
    Associations

    News

    Trials
    Company:
    Aurigene, Dr. Reddy’s
    Drug class:
    PD-L1 inhibitor, TIGIT inhibitor
    Related drugs:
    Associations

    News

    Trials
    5d
    JIVAN: A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies (clinicaltrials.gov)
    P1, N=21, Terminated, Aurigene Discovery Technologies Limited | N=30 --> 21 | Trial completion date: Jun 2025 --> Feb 2026 | Recruiting --> Terminated | Trial primary completion date: May 2025 --> Feb 2026; Patient recruitment problems
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • First-in-human
    |
    AUR-106
    2years
    JIVAN: A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies (clinicaltrials.gov)
    P1, N=30, Recruiting, Aurigene Discovery Technologies Limited | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • NCAM1 (Neural cell adhesion molecule 1)
    |
    AUR-106
    almost3years
    JIVAN: A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Aurigene Discovery Technologies Limited
    New P1 trial • Metastases
    |
    AUR-106